Even the first-generation compound crizotinib results in longer overall survival (OS) for ALK+ NSCLC patients compared to their TKI-treated EGFR+ counterparts (for example > 46 months in the PROFILE 1014 study vs. 39 and 32 months in the two arms of the FLAURA trial), while sequential ALK TKI, particularly with upfront administration of second-generation inhibitors such as alectinib, confer a median OS over five years, which is certainly one of the greatest successes in modern thoracic oncology [6, 8–10]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.